Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is a profitable gene therapy company with a successful commercial product and a diverse pipeline, including promising treatments for rare diseases and new indications, which could lead to significant revenue and stock value growth. Their current market leader for a rare condition has potential for international expansion and upcoming catalysts, particularly in their NK program, could further drive stock performance. While there are some concerns about expanding into new indications, the company's strong financials and promising treatments in eye conditions, cystic fibrosis, and lung cancer make it a solid investment opportunity.

Krystal Biotech is currently operating at a loss with a negative cash flow of $82 million in 2020 and an expected loss of $111 million in 2021. While their gene therapy platform has potential in the rare disease market, the company's success is highly reliant on regulatory approval, which could face challenges due to limited data and potential safety concerns. Additionally, competition in the gene therapy space is increasing, and the company's current lack of diversity in their product portfolio and reliance on a single commercial asset, Vyjuvek, puts them at risk in the long-term.